The incidence of bacteremia due to vancomycin-resistant Enterococcus (VRE) has increased markedly in recent years. We investigated the role of chloramphenicol in its treatment. All cases of VRE bacteremia occurring at our facility during a 45-month period were analyzed. The response to chloramphenicol, its effect on mortality, and the incidence of adverse effects were assessed. Fiftyone patients (65.4%) received chloramphenicol. Among patients in whom a response could be assessed, 22 (61.1%) of 36 demonstrated a clinical response, while 34 (79.1%) of 43 showed a microbiological response. Forty-two patients (53.8%) died as a result of the bacteremia. Although the mortality rate was lower for patients treated with chloramphenicol, the difference was not significant (odds ratio Å 0.72; 95% confidence interval, 0.28 -1.85; P Å .49), nor was there an association between earlier initiation of therapy and reduced mortality (P Å .45). In cases with central line -related bacteremia, there was no difference in mortality among patients treated with chloramphenicol, line removal, or both (P Å .36). Although 16 patients (31.4%) had adverse effects, none could be definitely attributed to chloramphenicol. Although chloramphenicol was well-tolerated, no significant effect of its use on mortality could be demonstrated.
Enterococcus is the second most commonly isolated nosocochloramphenicol resistance in enterococci has been demonstrated [11] , most VRE isolates are currently susceptible to this mial pathogen and the third most frequent cause of hospitalacquired bloodstream infection [1] . Vancomycin-resistant Enagent because of its previously infrequent use [12] . Although the utility of chloramphenicol in treating various types of VRE terococcus (VRE) in a clinical setting was first described in 1988 [2] . From 1989 to 1993, the percentage of nosocomial infections has been explored [8, 13, 14] , these studies have included only small numbers of patients and have provided enterococci resistant to vancomycin increased from 0.3% to 7.9% for all hospitalized patients and from 0.4% to 13.6% for little information on mortality or subsequent culture results.
In addition, analysis of mortality has been difficult because patients in intensive care units [3] . In addition, patients with VRE bloodstream infection have significantly higher rates of chloramphenicol is often used as a drug of last resort, frequently only for patients who are critically ill. mortality than do patients with bacteremia due to susceptible organisms [3] .
Vancomycin resistance is prevalent at our institution; we have found that 27.7% of all enterococcal bloodstream infecTo date, no consistently effective treatment for these resistant infections has emerged. In vitro and in vivo studies tions from 1993 to 1995 were due to vancomycin-resistant isolates [15] . Although the dominant strain of VRE is resistant have suggested possible roles for various combinations of penicillin/ampicillin, vancomycin, and gentamicin [4 -6], rito nearly all agents, few strains have demonstrated resistance to chloramphenicol. Use of this agent has been attempted for fampin [7] , doxycycline [8] , quinolones [9] , and quinupristin/dalfopristin [10] . Results of these studies, however, have these infections over the past several years. We analyzed all episodes of clinically significant VRE bacbeen inconclusive.
Another agent that has received attention as treatment for teremia occurring during a 45-month period to evaluate the effect of treatment with chloramphenicol. We documented the VRE bacteremia is chloramphenicol. Its general use in recent decades has been limited, largely because of its unfavorable proportion of patients who demonstrated a clinical and/or microbiological response to treatment, the effect of therapy on side-effect profile. Although the potential for emergence of mortality, and the incidence of possible adverse effects.
Data obtained for each patient at the time of bacteremia ity rate [16 -18] . Death occurring after a bacteremic episode but due to causes independent of the infectious process was included age, sex, ethnicity, hospital location, site of acquisition of infection, source of bacteremia, coinfecting organism(s), considered unrelated to bacteremia. An SOI score [16, 19] was assigned to each patient at the coexisting conditions, antimicrobial therapy in the preceding 30 days, number of days of hospitalization prior to onset of onset of bacteremia. The score was calculated as follows: change in mental status with disorientation Å 1 point, change bacteremia, total days of hospitalization, and severity of illness (SOI).
in mental status with stupor Å 2 points, change in mental status with coma Å 4 points, temperature of ú37.8ЊC Å 1 point, We documented the dose and duration of chloramphenicol therapy, how soon after the initial bacteremic episode therapy temperature of ú40.0ЊC Å 2 points, temperature of õ35.6ЊC Å 2 points, hypotension Å 2 points, mechanical ventilation Å was initiated, and whether any other antimicrobial agents or interventions were used to treat the bacteremia. Finally, we 2 points, and cardiac arrest Å 4 points. Assessment of response. Clinical outcome was classified documented the clinical and microbiological response to treatment, whether any adverse effects occurred, and the mortality as follows: (1) complete response -resolution of fever, leukocytosis, and all signs of infection; (2) partial response -abaterate.
Definitions. Clinically significant bacteremia was defined ment of the above parameters without complete resolution; (3) failure -absence of abatement or deterioration in any clinical by (1) isolation of VRE in two or more blood cultures or (2) isolation of VRE in a single blood culture if there was a cliniparameters; and (4) uncertain -intermittent or recurrent signs and symptoms of infection not clearly attributable to VRE [14] . cally apparent and/or culture-positive source of infection [10, 16, 17] . Cases in which there was only one positive blood Microbiological outcome was classified as follows: (1) definite response, sterile blood culture following a course of antimiculture and no clear clinical evidence of a source of infection were excluded.
crobial therapy active against VRE; (2) probable response, sterile blood culture result during a course of antimicrobial therapy Nosocomial bacteremia was defined as that occurring ú72 hours following admission to the hospital or in a patient who active against VRE; (3) failure, persistent isolation of VRE in blood cultures for a patient who received at least 5 days of had been hospitalized within the previous 2 weeks. Polymicrobial bacteremia was defined by the isolation of organisms in antimicrobial therapy active against VRE; and (4) uncertain, intermittent isolation of VRE in blood cultures with no clear addition to Enterococcus, either in the same blood culture or in multiple cultures of specimens taken during the same bactertemporal association with antimicrobial therapy or nonperformance of subsequent cultures to assess microbiological response emic episode.
The source of bacteremia was defined as a culture-positive [14] . Clinical and microbiological outcomes were assessed only after a patient had received chloramphenicol therapy for at least site or a clinically evident site of infection. Persistent bacteremia in a patient with a central venous catheter and no other 24 hours. Possible adverse effects of chloramphenicol occurring during obvious source was considered a catheter-related infection. If blood was the only source of a positive culture and there was therapy were documented and included a decrease in hemoglobin level of ú1 g/dL, a decrease in WBC count from normal to no other clear site of infection, the source of bacteremia was considered unknown.
õ2,000/mm 3 , or a decrease in platelet count to õ50,000/mm 3 . Evidence of hypersensitivity reactions (fever or rash) was also Coexisting conditions included hepatic dysfunction, malignancy, diabetes mellitus, renal insufficiency, HIV infection, sought. Microbiological methods. Blood culture specimens were neutropenia, corticosteroid use, and surgical procedure or trauma in the preceding 30 days. Hepatic dysfunction was deobtained by means of sterile venipuncture, and 10 -15 mL of blood was inoculated into aerobic and anaerobic BACTEC fined by two or more of the following: a bilirubin concentration of ú2.5 mg/dL, an aspartate aminotransferase or alanine amibottles (Becton-Dickinson, Towson, MD). Identification of enterococci and determination of susceptibility to vancomycin notransferase level more than twice normal, and known liver disease. Neutropenia was classified as an absolute neutrophil were done with use of standard microbiological methods that have been described previously [14] . VRE isolates are no count of õ500/mm 3 , while renal insufficiency was indicated by a calculated creatinine clearance of õ60 mL/min. Corticolonger routinely identified to the species level at our institution.
In the past, Ç98% of isolates demonstrating van A -type resissteroid use was defined as the receipt of prednisone at a dosage of 20 mg/d (or equivalent) for at least 2 weeks.
tance have been identified as Enterococcus faecium (personal communication, Paul H. Edelstein, 6 July 1998). Mortality directly attributable to bacteremia was defined as deaths in the setting of clinical evidence of active infection Statistical analysis. For categorical variables, proportions were compared by means of x 2 analysis. Continuous variables and a positive blood culture result. Mortality indirectly attributable to bacteremia was defined as deaths caused by failure or were analyzed with the Student's t test or the Wilcoxon ranksum test, depending on sample distribution. Multivariate analyfurther compromise of an organ system as a result of bacteremia. The proportion of deaths directly and indirectly attributsis was performed with logistic regression [20] . A two-tailed P value of õ.05 was considered significant. able to enterococcal bacteremia defined the attributable mortal-/ 9c5b$$no45
10-14- the organism was susceptible, and 1 (3.7%) was not treated The median age was 58 years (range, 16 -87 years), and 49 because the isolate was believed to represent contamination. patients (62.8%) were male. Sixty patients (76.9%) were white Of the 6 patients treated with other antibiotics, 3 received and 18 (23.1%) were black. The median duration of hospitalizarifampin and 1 each received penicillin, ampicillin, and cition was 37 days (range, 9 -377 days). Fifty-two patients profloxacin. (66.6%) were located on medical services, while 26 (33.3%)
The clinical and microbiological response of patients treated were on surgical services; 46 (59.0%) were located in an intenwith chloramphenicol is shown in table 1. Of 36 patients in sive care unit at the time of onset of bacteremia. The mean whom a clinical response could be ascertained, 22 (61.1%) number of antibiotic-days in the 30 days before the onset of demonstrated a complete or partial response. Of 43 patients bacteremia was 39.5 (range, 0 -85 days). The mean SOI score in whom a microbiological response could be ascertained, 34 was 3.9 (range, 0 -11).
(79.1%) showed a definite or probable response. The 78 patients with VRE bacteremia had many coexisting Among the 78 total patients, there were 42 deaths (53.8%) conditions: 39 (50.0%) had undergone a surgical procedure in directly or indirectly attributable to the bacteremia. These pathe preceding 30 days, 27 (34.6%) had renal insufficiency, tients were compared to those who were discharged or whose 25 (32.1%) had malignant disease, 21 (26.9%) had diabetes deaths were unrelated to the bacteremia (table 2) . Patients who mellitus, 19 (24.4%) had hepatic dysfunction, 19 (24.4%) had died as a result of the bacteremia were significantly more likely recently used steroids, and 3 (3.8%) were infected with HIV.
to have had diabetes, recent surgery, and a respiratory source Of 78 cases of VRE bloodstream infection, 34 (43.6%) were of infection and to have been located in the surgical intensive attributed to a central venous catheter. In addition, an abdomicare unit or oncology unit. In addition, they had a significantly nal source was implicated in 11 cases (14.1%), while 10 pagreater mean SOI score. Although the mortality rate was lower tients (12.8%) were noted to have a urinary source of infection.
for patients treated with chloramphenicol, the difference was Of 78 total episodes of bacteremia, 76 (97.4%) were nosoconot significant. Of 51 patients who received chloramphenicol, mial. Although the bacteremia of two patients was classified 26 (51.0%) died because of the bacteremia, while of the 27 as community-acquired because they had not been in the hospipatients who did not receive the drug, 16 (59.3%) died as a tal in the previous 2 weeks, both had been hospitalized within result of the bacteremia (OR Å 0.72; 95% CI, 0.28 -1.85; the previous 30 days. Twenty-six episodes of bacteremia P Å .49 by x 2 analysis). (33.3%) were polymicrobial. The coinfecting organisms were The mean SOI score for patients treated with chloramphenicoagulase-negative staphylococci, 12 episodes (46.2%); gramcol was 3.6, compared to 4.4 for those patients not treated with negative rods, 6 (23.1%); methicillin-resistant Staphylococcus this agent (P Å .13 by Student's t test). The factors associated aureus, 5 (19.2%); Candida albicans, 2 (7.7%); and both gramwith mortality on univariate analysis were then included in a negative rods and coagulase-negative staphylococci, 1 (3.8%). multivariate model, which revealed that only the mean SOI The distribution of the specific coinfecting organisms was simiscore remained independently associated with increased morlar among patients who were and were not treated with chloramphenicol.
The median duration of hospitalization prior to onset of bacteremia was 23 days (range, 1 -224 days). The median dura- (range, 0.9 -7.9 days). The median duration from identification tality (OR Å 2.66; 95% CI, 1.70 -4.16; P õ .001, per 1-point 30 patients, 9 were treated only with chloramphenicol (without line removal), 14 received chloramphenicol and had the line increase in mean SOI score).
We noted no significant effect of the time interval from the removed, and 7 received no chloramphenicol but had the line removed. The mortality rates in these three groups were 22.2%, onset of the bacteremic episode to initiation of chloramphenicol treatment and death. For patients who died because of the 50.0%, and 42.9%, respectively (P Å .36 by x 2 analysis). The mean SOI scores for the three groups were 3.2, 3.4, and 3.0, bacteremia, the median duration from onset of bacteremia to initiation of chloramphenicol was 3.0 days (range, 0.9 -7.9 respectively (P Å .93 by Student's t-test).
Sixteen patients had a total of 24 episodes of neutropenia, days), while for those whose death was unrelated to the bacteremia, the median duration was 2.7 days (range, 1.2 -7.2 days) anemia, or thrombocytopenia (3, 8, and 13 events, respectively). In none of these 24 cases, however, could the adverse (P Å .45 by Wilcoxon's rank-sum test).
Of 34 patients with central catheter -related infections, four effect be definitely ascribed to treatment with chloramphenicol, as other ongoing disease processes or concurrent therapies died before culture results identified VRE. Of the remaining / 9c5b$$no45
10-14-98 12:18:30 cida UC: CID could also have been responsible. Only five patients had chlorlikely excluding from analysis those patients who were more gravely ill [14] . amphenicol therapy discontinued because of possible adverse effects, but in none of these cases did this discontinuation result To our knowledge, our study is to date by far the largest to evaluate the role of chloramphenicol in VRE infection. Furtherin resolution of the abnormality. more, we included only those patients with bloodstream involvement.
Discussion
We found that Ç70% of all cases of VRE bacteremia were secondary to a central venous catheter or an abdominal or During the 1980s, the incidence of enterococcal bloodstream infection in teaching hospitals increased by 120% -197% [21] .
urinary tract source. Although we noted other patients to have clinical and microbiological evidence of primary skin/soft tisSince the first description of VRE in a clinical setting nearly 1 decade ago [2], the percentage of nosocomial enterococci sue or pulmonary infection, it is often difficult to ascertain the true significance of positive cultures of specimens from these resistant to vancomycin has likewise increased sharply [3] . Of concern is that mortality rates are significantly higher among sites. Although it is possible these cultures may represent colonization, in the absence of another possible site of primary patients with VRE bloodstream infections than among patients with bacteremia due to susceptible organisms [3] , with a recent infection, these sites were considered to be the source of the bacteremia, according to our definitions. report estimating the attributable mortality of VRE bacteremia to be Ç37% [22] .
Of those patients in whom a clinical response could be ascertained, nearly two-thirds had some response. Unfortunately, in No consistently effective treatment for these resistant infections has emerged to date. In vitro studies have suggested over one-third of patients a clinical response could not be accurately assessed, because of the often multiple concurrent possible roles for various combinations of penicillin/ampicillin, vancomycin, and gentamicin [5, 6], rifampin [7] , and several illnesses and frequent interventions. We noted that an even greater percentage of patients had a microbiological response; quinolones [9] . Proposed regimens based on in vivo data have included high-dose continuous-infusion ampicillin or ampicilof the patients in whom a response could be assessed, the bloodstream of nearly 80% cleared either during or after comlin/sulbactam [23], a combination of two cell-wall-active agents plus gentamicin [4], oral novobiocin plus intravenous cipletion of chloramphenicol therapy. The evaluation of the response to therapy may be affected profloxacin [10] , and doxycycline [8] . The results of these studies have been inconclusive, however. Quinupristin/dalfoby the case definition, particularly since isolation of VRE may represent colonization rather than true infection. Includpristin is another agent suggested as potential therapy for VRE infection [10] . However, the development of in vitro resistance ing all patients with a positive blood culture, as has been done in other reports [22] , would undoubtedly include some to this agent has been noted during treatment for VRE bacteremia, suggesting that therapy with this agent alone may not be cases of colonization. In an effort to minimize this risk, our case definition, which has been used in past reports [10, sufficient [24] .
Chloramphenicol has likewise gained attention as a possible 16, 17] , included only patients who had either two or more positive cultures or one positive culture with a clinical or therapeutic agent against VRE infections, although its efficacy remains unproven. Past studies attempting to define the role of microbiological source of infection elsewhere. This definition, however, might have resulted in the exclusion of a chloramphenicol have included only small numbers of patients and yielded few data on mortality or subsequent culture results few cases in which one positive culture represented a true transient bacteremia with no other clinical evidence of infec-[8, 13, 14] . In addition, this agent has often been used as a drug of last resort and only for those patients who are critically tion. During the study period we identified 98 cases of VRE bacteremia, of which 86 met our criteria for clinically sigill, making analysis of mortality difficult.
In a study of 32 liver-transplant recipients with VRE bacternificant. This suggests that, at most, 12 possible true VRE infections were excluded by our definition. emia, 16 patients received chloramphenicol, of whom 6 died [8] . Although this agent did not influence the mortality rate, it Although we noted a lower mortality rate among patients treated with chloramphenicol, our study was somewhat limited was given only to the most severely ill patients [8] . Unfortunately, there were no follow-up culture data to assess the effiby the relatively small sample size. We calculated an odds ratio of 0.72 for the association of chloramphenicol treatment and cacy of chloramphenicol in clearing the bloodstream [8] . Hardalo et al. noted that while only four of 11 patients with VRE mortality, suggesting there may be a protective effect of therapy with this agent. However, we did not have sufficient power to infection were cured with chloramphenicol, for two-thirds of those who died, cultures had become sterile during treatment determine whether this was a true association. Our study did, however, have 80% power to detect a 2.5-fold difference in prior to death [13] . Finally, a study at our center evaluated 16 patients with VRE infections treated with chloramphenicol mortality, depending on whether patients were or were not treated with chloramphenicol. This suggests that if there is a [14] . Although the majority of patients demonstrated some clinical and microbiological response, only those patients who protective effect of treatment with this agent, it is likely not substantial. received chloramphenicol for at least 3 days were included, / 9c5b$$no45
10-14-98 12:18:30 cida UC: CID Another limitation of this study is the possible selection bias VRE bacteremia -related mortality. This association was not significant in our limited sample, and these results should be introduced in determining which patients received chloramphenicol. A large proportion of patients not treated with this agent died explored with greater numbers of patients in a controlled or prospective study. In addition, for patients with central linebefore susceptibility data were available, perhaps resulting in more critically ill patients not receiving chloramphenicol, and thus makrelated bloodstream infections, prompt removal of the catheter may permit limited or no treatment with chloramphenicol. ing the mortality rate in the group of patients treated with chloramphenicol appear artificially low. We believe this is unlikely, however, since there was no significant difference when comparing
